CAJ | 학술논문

目的探讨自动乳腺全容积扫描(automated breast volume scanner,ABVS)冠状面汇聚征对乳腺浸润性导管癌(infiltrating ductal carcinoma,IDC)治疗敏感性及其预后的预测价值.方法选取于本院行乳腺癌根治性切除术、病理诊断为IDC的患者46例,共47个病灶,分析病灶ABVS冠状面汇聚征与其临床病理[病灶大小、病理组织学分级、腋窝淋巴结状态以及雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体(HER2)表达]的相关性.结果汇聚征在不同大小和不同腋窝淋巴结状态IDC组中出现比例差异无统计学意义(P＞0.05).汇聚征在病理分级Ⅱ级组中出现的比例高于Ⅲ级组,差异有统计学意义(P=0.008).汇聚征在ER阳性组出现的比例高于ER阴性组,但差异无统计学意义(P=0.055);在PR阳性组出现的比例高于PR阴性组,差异有统计学意义(P=0.004);在HER2阴性组出现的比例高于HER2阳性组,差异有统计学意义(P=0.019).结论汇聚征对IDC治疗敏感性及其预后有一定的预测价值.
목적 탐토자동유선전용적소묘(automated breast volume scanner,ABVS)관상면회취정대유선침윤성도관암(infiltrating ductal carcinoma,IDC)치료민감성급기예후적예측개치.방법 선취우본원행유선암근치성절제술、병리진단위IDC적환자46례,공47개병조,분석병조ABVS관상면회취정여기림상병리[병조대소、병리조직학분급、액와림파결상태이급자격소수체(ER)、잉격소수체(PR)、인표피생장인자수체(HER2)표체]적상관성.결과 회취정재불동대소화불동액와림파결상태IDC조중출현비례차이무통계학의의(P＞0.05).회취정재병리분급Ⅱ급조중출현적비례고우Ⅲ급조,차이유통계학의의(P=0.008).회취정재ER양성조출현적비례고우ER음성조,단차이무통계학의의(P=0.055);재PR양성조출현적비례고우PR음성조,차이유통계학의의(P=0.004);재HER2음성조출현적비례고우HER2양성조,차이유통계학의의(P=0.019).결론 회취정대IDC치료민감성급기예후유일정적예측개치.
Objective To explore the value of convergence symptom in predicting the treatment sensitivity and the prognosis of patients with breast infiltrating ductal carcinoma (IDC).Methods A retrospective review was performed in 46 women with 47 IDC lesions.Correlation between clinicopathological characteristics and convergence symptom was analyzed.Clinicopathological characteristics included tumor size,tumor grade,axillary lymph node state and the expression of ER,PR and H ER2.Results There was no obvious difference within different IDC groups by tumor size or axillary lymph node state in the presentation of convergence symptom (P ＞ 0.05).The convergence symptom was more common in grade Ⅱ IDC lesions than in grade Ⅲ IDC lesions and the difference was statistically significant (P =0.008).No difference was found between the presentation of convergence symptom and the expression of ER (P =0.055).Significant correlations were found between the presentation of convergence symptom and the expression of PR and HER2 (P ＜0.05).Conclusions Convergence symptom is helpful in predicting the treatment sensitivity and the prognosis of patients with breast infiltrating ductal carcinoma.